

CR
R
JOURNAL
OF CARDIORESPIRATORY RESEARCH

ISSN 2181-0974
DOI 10.26739/2181-0974
Impact Factor SJIF 2022: 5.937

Journal of
CARDIORESPIRATORY
RESEARCH



Volume 6, Issue 2

2025

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал кардиореспираторных исследований

JOURNAL OF CARDIORESPIRATORY RESEARCH

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный
медицинский университет

Tadqiqot.uz

Ежеквартальный
научно-практический
журнал

ISSN: 2181-0974
DOI: 10.26739/2181-0974



N° 2
2025

Главный редактор:

Ташкенбаева Элеонора Негматовна

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней и кардиологии №2 Самаркандского Государственного медицинского университета, председатель Ассоциации терапевтов Самаркандской области.
<https://orcid.org/0000-0001-5705-4972>

Заместитель главного редактора:

Хайбулина Зарина Руслановна

*доктор медицинских наук, руководитель отдела биохимии с группой микробиологии
ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0002-9942-2910>*

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:

Аляви Анис Лютфуллаевич

академик АН РУз, доктор медицинских наук, профессор, Председатель Ассоциации Терапевтов Узбекистана, Советник директора Республиканского специализированного научно-практического центра терапии и медицинской реабилитации (Ташкент)
<https://orcid.org/0000-0002-0933-4993>

Бокерия Лео Антонович

академик РАН, доктор медицинских наук, профессор, Президент научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева (Москва), <https://orcid.org/0000-0002-6180-2619>

Курбанов Равшанбек Давлетович

академик АН РУз, доктор медицинских наук, профессор, Советник директора Республиканского специализированного научно-практического медицинского центра кардиологии (Ташкент), <https://orcid.org/0000-0001-7309-2071>

Шкляев Алексей Евгеньевич

д.м.н., профессор, ректор Федерального государственного бюджетного образовательного учреждения высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации

Michał Tendera

профессор кафедры кардиологии Верхнесилезского кардиологического центра, Силезский медицинский университет в Катовице, Польша (Польша)
<https://orcid.org/0000-0002-0812-6113>

Покушалов Евгений Анатольевич

доктор медицинских наук, профессор, заместитель генерального директора по науке и развитию сети клиник «Центр новых медицинских технологий» (ЦНМТ), (Новосибирск), <https://orcid.org/0000-0002-2560-5167>

Зуфаров Миржамол Мирумарович

доктор медицинских наук, профессор, руководитель отдела ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0003-4822-3193>

Акилов Хабибулла Атауллаевич

доктор медицинских наук, профессор, Директор Центра развития профессиональной квалификации медицинских работников (Ташкент)

Насирова Зарина Акбаровна

DSc, доцент кафедры внутренних болезней и кардиологии №2 Самаркандского Государственного Медицинского университета (ответственный секретарь) ORCID: 0000-0002-8722-0393 (ответственный секретарь)

Ризаев Жасур Алимджанович

доктор медицинских наук, профессор, Ректор Самаркандского государственного медицинского университета, <https://orcid.org/0000-0001-5468-9403>

Зиядуллаев Шухрат Худойбердиевич

доктор медицинских наук, профессор, заместитель директора по научной работе института иммунологии и геномики человека АН РУз <https://orcid.org/0000-0002-9309-3933>

Джан Ковак

Профессор, председатель Совета Европейского общества кардиологов по инсульту, руководитель специализированной кардиологии, заведующий отделением кардиологии, кардио- и торакальной хирургии, консультант-кардиолог, больница Гленфилд, Лестер (Великобритания)

Сергио Бернардини

Профессор клинической биохимии и клинической молекулярной биологии, главный врач отдела лабораторной медицины, больница Университета Тор Вергата (Рим, Италия)

Ливерко Ирина Владимировна

доктор медицинских наук, профессор, заместитель директора по науке Республиканского специализированного научно-практического медицинского центра фтизиатрии и пульмонологии Республики Узбекистан (Ташкент)
<https://orcid.org/0000-0003-0059-9183>

Цурко Владимир Викторович

доктор медицинских наук, профессор Первого Московского государственного медицинского университета им. И.М. Сеченова (Москва)
<https://orcid.org/0000-0001-8040-3704>

Тригулова Раиса Хусаиновна

Доктор медицинских наук, руководитель лаборатории превентивной кардиологии, ведущий научный сотрудник лаборатории ИБС и атеросклероза. Республиканский специализированный научно-практический медицинский центр кардиологии (Ташкент)
ORCID- 0000-0003-4339-0670

Тураев Феруз Фатхуллаевич

доктор медицинских наук, Директор Республиканского специализированного научно-практического медицинского центра эндокринологии имени академика Ю.Г. Туракулова

Bosh muharrir:

Tashkenbayeva Eleonora Negmatovna

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini mudiri, Samarqand viloyati vrachlar uyushmasi raisi
<https://orcid.org/0000-0001-5705-4972>

Bosh muharrir o'rinbosari:

Xaibulina Zarina Ruslanovna

tibbiyot fanlari doktori, "akad V. Vohidov nomidagi RIJM davlat institutining mikrobiologiya guruhi bilan biokimyo kafedrasini mudiri" <https://orcid.org/0000-0002-9942-2910>

TAHRIRIYAT A'ZOLARI:

Alyavi Anis Lyutfullayevich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, O'zbekiston Terapevtlar uyushmasi raisi, Respublika ixtisoslashtirilgan ilmiy va amaliy tibbiy terapiya markazi va tibbiy reabilitatsiya direktori maslahatchisi (Toshkent), <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Rossiya fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, A.N. Bakuleva nomidagi yurak-qon tomir jarrohligi ilmiy markazi prezidenti (Moskva) <https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davlatovich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazining direktori maslahatchisi (Toshkent) <https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Tibbiyot fanlari doktori, professor, Rossiya Federatsiyasi Sog'liqni saqlash vazirligining "Izhevsk davlat tibbiyot akademiyasi" Federal davlat byudjeti oliy ta'lim muassasasi rektori

Mixal Tendera

Katovitsadagi Sileziya Tibbiyot Universiteti, Yuqori Sileziya Kardiologiya Markazi kardiologiya kafedrasini professori (Polsha) <https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeniy Anatolevich

tibbiyot fanlari doktori, professor, "Yangi tibbiy texnologiyalar markazi" (YTTM) klinik tarmog'ining ilmiy ishlar va rivojlanish bo'yicha bosh direktorining o'rinbosari (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Zufarov Mirjamol Mirumarovich

tibbiyot fanlari doktori, professor, "akad V. Vohidov nomidagi RIJM davlat muassasasi" bo'limi boshlig'i" <https://orcid.org/0000-0003-4822-3193>

Akilov Xabibulla Ataulayevich

tibbiyot fanlari doktori, professor, Tibbiyot xodimlarining kasbiy malakasini oshirish markazi direktori (Toshkent)

Nasirova Zarina Akbarovna

Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini dotsenti, DSc (mas'ul kotib) ORCID: 0000-0002-8722-0393 (mas'ul kotib)

Rizayev Jasur Alimjanovich

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti rektori <https://orcid.org/0000-0001-5468-9403>

Ziyadullayev Shuxrat Xudoyberdiyevich

tibbiyot fanlari doktori, professor, O'zbekiston Respublikasi Fanlar akademiyasi Immunologiya va inson genomikasi instituti ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent) <https://orcid.org/0000-0002-9309-3933>

Jan Kovak

Yevropa kardiologiya jamiyati insult kengashi raisi, 2017 yildan buyon ixtisoslashtirilgan kardiologiya kafedrasini rahbari, kardiologiya, yurak va torakal jarrohlik kafedrasini mudiri, maslahatchi kardiolog Glenfild kasalxonasi, Lester (Buyuk Britaniya)

Sergio Bernardini

Klinik biokimyo va klinik molekulyar biologiya bo'yicha professor - Laboratoriya tibbiyoti bo'limi bosh shifokori – Tor Vergata universiteti kasalxonasi (Rim-Italiya)

Liverko Irina Vladimirovna

tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan fiziologiya va pulmonologiya ilmiy-amaliy tibbiyot markazining ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent) <https://orcid.org/0000-0003-0059-9183>

Surko Vladimir Viktorovich

tibbiyot fanlari doktori, professori I.M. Sechenov nomidagi Birinchi Moskva Davlat tibbiyot universiteti (Moskva) <https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Xusainovna

Tibbiyot fanlari doktori, Profilaktik kardiologiya laboratoriyasi mudiri, YuIK va ateroskleroz laboratoriyasining yetakchi ilmiy xodimi. Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi (Toshkent) ORCID- 0000-0003-4339-0670

Turayev Feruz Fatxullayevich

tibbiyot fanlari doktori, akademik Y.X.To'raqulov nomidagi Respublika ixtisoslashtirilgan endokrinologiya ilmiy amaliy tibbiyot markazi direktori <https://orcid.org/0000-0002-1321-4732>

Chief Editor:

Tashkenbaeva Eleonora Negmatovna*Doctor of Medical Sciences, professor, Head of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University, Chairman of the Association of Physicians of the Samarkand Region. <https://orcid.org/0000-0001-5705-4972>*

Deputy Chief Editor:

Xaibulina Zarina Ruslanovna*Doctor of Medical Sciences, Head of the Department of Biochemistry with the Microbiology Group of the State Institution "RSSC named after acad. V. Vakhidov", <https://orcid.org/0000-0002-9942-2910>*

MEMBERS OF THE EDITORIAL BOARD:

Alyavi Anis Lutfullaevich*Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Chairman of the Association of Physicians of Uzbekistan, Advisor to the Director of the Republican Specialized Scientific - Practical Center of Therapy and Medical Rehabilitation (Tashkent) <https://orcid.org/0000-0002-0933-4993>***Bockeria Leo Antonovich***Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, President of the Scientific Center for Cardiovascular Surgery named after A.N. Bakuleva (Moscow) <https://orcid.org/0000-0002-6180-2619>***Kurbanov Ravshanbek Davletovich***Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Advisor to the Director Republican Specialized Scientific and Practical Medical Center of Cardiology, (Tashkent) <https://orcid.org/0000-0001-7309-2071>***Shklyayev Aleksey Evgenievich***Doctor of Medical Sciences, Professor, Rector of the Federal State Budgetary Educational Institution of Higher Education "Izhevsk State Medical Academy" of the Ministry of Health of the Russian Federation***Michal Tendera***Professor of the Department of Cardiology, Upper Silesian Cardiology Center, Silesian Medical University in Katowice, Poland (Poland) <https://orcid.org/0000-0002-0812-6113>***Pokushalov Evgeny Anatolyevich***Doctor of Medical Sciences, Professor, Deputy Director General for Science and Development of the Clinic Network "Center for New Medical Technologies" (CNMT), (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>***Akilov Xabibulla Ataulaevich***Doctor of Medical Sciences, Professor, Center for the development of professional qualifications of medical workers (Tashkent)***Nasyrova Zarina Akbarovna***DSc, Associate Professor of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University (Executive Secretary) ORCID: 0000-0002-8722-0393 (Executive Secretary)***Rizaev Jasur Alimjanovich***Doctor of Medical Sciences, Professor, Rector of the Samarkand State Medical University <https://orcid.org/0000-0001-5468-9403>***Ziyadullaev Shuhrat Khudoyberdievich***Doctor of Medical Sciences, Professor, Deputy Director for Scientific Work of the Institute of Human Genomics Immunology of the Academy of Sciences of the Republic of Uzbekistan. <https://orcid.org/0000-0002-9309-3933>***Jan Kovac***Professor Chairman, European Society of Cardiology Council for Stroke, Lead of Specialised Cardiology, Head of Cardiology, Cardiac and Thoracic Surgery, Consultant Cardiologist, Glenfield Hospital, Leicester (United Kingdom)***Sergio Bernardini***Full Professor in Clinical Biochemistry and Clinical Molecular Biology -Head Physician of the Laboratory Medicine Unit- University of Tor Vergata Hospital (Rome-Italy)***Liverko Irina Vladimirovna***Doctor of Medical Sciences, Professor, Deputy Director for Science of the Republican Specialized Scientific and Practical Medical Center for Phthiology and Pulmonology of the Republic of Uzbekistan (Tashkent) <https://orcid.org/0000-0003-0059-9183>***Zufarov Mirjamol Mirumarovich***Doctor of Medical Sciences, Professor, Head of the Department of the State Institution "RSNPMTSH named after acad. V. Vakhidov" <https://orcid.org/0000-0003-4822-3193>***Tsurko Vladimir Viktorovich***Doctor of Medical Sciences, professor Of Moscow State Medical University by name I.M. Sechenov (Moscow) <https://orcid.org/0000-0001-8040-3704>***Trigulova Raisa Khusainovna***Doctor of Medical Sciences, Head of the Laboratory of Preventive Cardiology, Leading Researcher of the Laboratory of IHD and Atherosclerosis. Republican Specialized Scientific and Practical Medical Center of Cardiology (Tashkent) ORCID- 0000-0003-4339-0670***Turaev Feruz Fatxullaevich***Doctor of Medical Sciences, Director of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Yu.G. Turakulova*

Алимов Дониёр Анварович
доктор медицинских наук, директор
Республиканского научного центра
экстренной медицинской помощи

Янгиев Бахтиёр Ахмедович
кандидат медицинских наук,
директор Самаркандского филиала
Республиканского научного центра
экстренной медицинской помощи

Абдуллаев Акбар Хатамович
доктор медицинских наук, главный
научный сотрудник Республиканского
специализированного научно-
практического центра медицинской
терапии и реабилитации
<https://orcid.org/0000-0002-1766-4458>

Агабабян Ирина Рубеновна
кандидат медицинских наук, доцент,
заведующая кафедрой терапии ФПДО,
Самаркандского Государственного
медицинского института

Алиева Нигора Рустамовна
доктор медицинских наук, заведующая
кафедрой Госпитальной педиатрии №1
с основами нетрадиционной медицины
ТашПМИ

Исмаилова Адолат Абдурахимовна
доктор медицинских наук, профессор,
заведующая лабораторией
фундаментальной иммунологии
Института иммунологии геномики
человека АН РУз

Камалов Зайнитдин Сайфутдинович
доктор медицинских наук, профессор,
заведующий лабораторией
иммунорегуляции Института
иммунологии и геномики
человека АН РУз

Каюмов Улугбек Каримович
доктор медицинских наук, профессор,
заведующий кафедрой внутренних
болезней и телемедицины Центра
развития профессиональной
квалификации медицинских работников

Хусинова Шоира Акбаровна
кандидат философских наук, доцент,
заведующая кафедрой общей практики,
семейной медицины ФПДО
Самаркандского Государственного
медицинского института

Шодикүлова Гуландом Зикрияевна
д.м.н., профессор, заведующая
кафедрой внутренних болезней № 3
Самаркандского Государственного
Медицинского Института
(Самарканд)
<https://orcid.org/0000-0003-2679-1296>

Alimov Doniyor Anvarovich
*tibbiyot fanlari doktori, Respublika
shoshilinch tibbiy yordam ilmiy
markazi direktori (Toshkent)*

Yangiyev Baxtiyor Axmedovich
*tibbiyot fanlari nomzodi,
Respublika shoshilinch tibbiy
yordam ilmiy markazining
Samarqand filiali direktori*

Abdullayev Akbar Xatamovich
*tibbiyot fanlari doktori, O'zbekiston
Respublikasi Sog'liqni saqlash
vazirligining "Respublika
ixtisoslashtirilgan terapiya va tibbiy
reabilitatsiya ilmiy-amaliy
tibbiyot markazi" davlat
muassasasi bosh ilmiy xodimi
<https://orcid.org/0000-0002-1766-4458>*

Agababayan Irina Rubenovna
*tibbiyot fanlari nomzodi, dotsent,
DKTF, terapiya kafedrasini mudiri,
Samarqand davlat tibbiyot instituti*

Alieva Nigora Rustamovna
*tibbiyot fanlari doktori, 1-sonli
gospital pediatriya kafedrasini mudiri,
ToshPTI*

Ismoilova Adolat Abduraximovna
*tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Odam genomikasi
immunologiyasi institutining
fundamental immunologiya
laboratoriyasining mudiri*

Kamalov Zaynitdin Sayfutdinovich
*tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Immunologiya va
inson genomikasi institutining
Immunogenetika laboratoriyasi mudiri*

Qayumov Ulug'bek Karimovich
*tibbiyot fanlari doktori, professor,
Tibbiyot xodimlarining kasbiy
malakasini oshirish markazi, ichki
kasalliklar va teletibbiyot kafedrasini
mudiri (Toshkent)*

Xusinova Shoira Akbarovna
*tibbiyot fanlari nomzodi, dotsent,
Samarqand davlat tibbiyot instituti
DKTF Umumiy amaliyot va oilaviy
tibbiyot kafedrasini mudiri (Samarqand)*

Shodikulova Gulandom Zikriyayevna
*tibbiyot fanlari doktori, professor,
Samarqand davlat tibbiyot instituti 3-
ichki kasalliklar kafedrasini mudiri
(Samarqand)
<https://orcid.org/0000-0003-2679-1296>*

Alimov Doniyor Anvarovich
*Doctor of Medical Sciences, Director of
the Republican Scientific Center of
Emergency Medical Care*

Yangiev Bakhtiyor Axmedovich
*PhD, Director of Samarkand branch of
the Republican Scientific Center of
Emergency Medical Care*

Abdullaev Akbar Xatamovich
*Doctor of Medical Sciences,
Chief Researcher of the State Institution
"Republican Specialized Scientific and
Practical Medical Center for Therapy and
Medical Rehabilitation" of the Ministry of
Health of the Republic of Uzbekistan,
<https://orcid.org/0000-0002-1766-4458>*

Agababayan Irina Rubenovna
*PhD, Associate Professor, Head of the
Department of Therapy, FAGE,
Samarkand State Medical Institute*

Alieva Nigora Rustamovna
*Doctor of Medical Sciences, Head of the
Department of Hospital Pediatrics
No. 1 with the basics of alternative
medicine, TashPMI*

Ismailova Adolat Abduraximovna
*doctor of Medical Sciences, Professor,
Head of the Laboratory of Fundamental
Immunology of the Institute of
Immunology of Human
Genomics of the Academy of Sciences
of the Republic of Uzbekistan*

Kamalov Zainitdin Sayfutdinovich
*doctor of Medical Sciences, Professor,
Head of the Laboratory of
Immunogenetics of the Institute of
Immunology and Human Genomics
of the Academy of Sciences of the
Republic of Uzbekistan*

Kayumov Ulugbek Karimovich
*Doctor of Medical Sciences, Professor,
Head of the Department of Internal
Diseases and Telemedicine of the Center
for the development of professional
qualifications
of medical workers*

Khusinova Shoira Akbarovna
*PhD, Associate Professor, Head of the
Department of General Practice,
Family Medicine FAGE of the
Samarkand State Medical Institute*

Shodikulova Gulandom Zikriyayevna
*Doctor of Medical Sciences, professor,
head of the Department of Internal
Diseases N 3 of Samarkand state medical
institute (Samarkand)
<https://orcid.org/0000-0003-2679-1296>*

Халиков Каххор Мирзаевич
кандидат медицинских наук, доцент
заведующий кафедрой биологической
химии Самаркандского
государственного медицинского
университета

Аннаев Музаффар
Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Тулабаева Гавхар Миракбаровна
Заведующая кафедрой кардиологии,
Центр развития профессиональной
квалификации медицинских
работников, д.м.н., профессор

**Абдумаджидов Хамидулла
Амануллаевич**
Бухарский государственный
медицинский институт имени Абу
Али ибн Сино. Кафедра «Хирургические
болезни и реанимация». Доктор
медицинских наук, профессор.

Саидов Максуд Арифович
к.м.н., директор Самаркандского
областного отделения
Республиканского специализированного
научно-практического медицинского
центра кардиологии (г. Самарканд)

Срождинова Нигора Зайнутдиновна
д.м.н. Заведующая научно-
исследовательской лабораторией
кардиодиабета и метаболических
нарушений РСНПМЦК

Xalikov Qaxxor Mirzayevich
Tibbiyot fanlari nomzodi, dotsent
Samarqand davlat tibbiyot universiteti
Biologik kimyo kafedrasini mudiri

Annayev Muzaffar G'iyos o'g'li
Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib)

Tulabayeva Gavxar Mirakbarovna
kardiologiya kafedrasini mudiri, tibbiyot
xodimlarining kasbiy malakasini rivojlantirish
markazi, tibbiyot fanlari doktori, professor

Abdumadjidov Xamidulla Amanullayevich
«Abu Ali ibn Sino nomidagi Buxoro davlat
tibbiyot oliygohi» Xirurgiya kasalliklari va
reanimatsiya kafedrasini proffessori, tibbiyot
fanlari doktori.

Saidov Maqsud Arifovich
tibbiyot fanlari nomzodi,
Respublika ixtisoslashgan kardialogiya
ilmiy amaliy tibbiyot markazi Samarqand
viloyat mintaqaviy filiali direktori
(Samarqand)

Srojidinova Nigora Zaynutdinovna
t.f.d. Kardiodiabet va metabolik buzilishlar
ilmiy tadqiqot laboratoriyasi mudiri

Khalikov Kakhor Mirzayevich
Candidate of Medical Sciences,
Associate Professor, Head of the Department
of Biological Chemistry, Samarkand State
Medical University

Annaev Muzaffar
Assistant of the Department of Internal
Diseases and Cardiology No. 2 of the
Samarkand State Medical University
(technical secretary)

Tulabayeva Gavkhar Mirakbarovna
Head of the Department of Cardiology,
Development Center professional
qualification of medical workers,
MD, professor

**Abdumadjidov Khamidulla
Amanullayevich**
“Bukhara state medical institute named
after Abu Ali ibn Sino”. DSc, professor.

Saidov Maksud Arifovich
Candidate of Medical Sciences, Director
of the Samarkand Regional Department of
the Republican Specialized Scientific and
Practical Medical Center of Cardiology
(Samarkand)

Srojidinova Nigora Zaynutdinovna
DSc, Head of Cardiodiabetes and Metabolic
Disorders Laboratory

СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ

1	И.Р. Агабабян, З.К. Юсупова Новые возможности терапии неконтролируемой артериальной гипертензии I.R. Agababayan, Z.K. Yusupova New treatment options for uncontrolled arterial hypertension I.R. Agababayan, Z.K. Yusupova Nazorat qilinmaydigan arterial gipertenziyani davolashning yangi imkoniyatlari.....	11
2	И.Р. Агабабян, С.Б. Рустамова Роль эпикардиальной жировой ткани в развитии хронической сердечной недостаточности I.R. Agababayan, S.B. Rustamova The role of epicardial adipose tissue in the development of chronic heart failure I.R. Agababayan, S.B. Rustamova Surunkali yurak yetishmovchiligi rivojlanishida epikardial yog‘ to‘qimasining roli.....	16
3	Б.Н. Баймуратова, А.К. Жиен, М.А. Таскынова, З.Я. Шерматова Эффективность комбинации валодипа при артериальной гипертензии B.N. Baimuratova, A.K. Zhien, M.A. Taskynova, Z.Ya. Shermatova Effectiveness of the valodip combination in arterial hypertension B.N. Baymuratova, A.K. Jiyeen, M.A. Taskynova, Z.Ya. Shermatova Arterial gipertenziyada valodip kombinatsiyasining samaradorligi.....	21
4	М.С. Бекмурадова Эхокардиографические изменения при гипертонической болезни у пожилых M.S. Bekmuradova Echocardiographic changes in hypertension in the elderly patients M.S. Bekmuradova Keksa bemorlarda gipertoniya kasalligining exokardiografik o‘zgarishlari.....	25
5	С.А. Закирова И.Р. Агабабян Оценка эффективности комбинированного применения антагонистов рецепторов ангиотензина II и сердечных гликозидов при гипертонической болезни, осложненной хронической сердечной недостаточностью и фибрилляцией предсердий S. A Zakirova., I.R. Agababayan Evaluation of the effectiveness of combined use of angiotensin II receptor antagonists and cardiac glycosides in hypertension complicated by chronic heart failure and atrial fibrillation S. A Zakirova., I.R. Agababayan Surunkali yurak yetishmovchiligi va bo‘lmachalar fibrillyatsiyasi bilan asoratlangan gipertoniya kasalligida angiotenzin II retseptorlari antagonistlari va yurak glikozidlarini birgalikda qo‘llash samaradorligini baholash.....	30
6	Д.Ж. Камолова, М.Т. Эргашева, З.Э. Хайдарова Факторы профилактики и лечения артериальной гипертонии во время беременности D.J. Kamolova, M.T. Ergasheva, Z.E. Haydarova Factors for the prevention and management of arterial hypertension in pregnancy D.J. Kamolova, M.T. Ergasheva, Z.E. Haydarova Homiladorlik davrida arterial gipertenziyaning oldini olish va davolash omillari.....	34
7	А.О. Лаханов, Э.Н. Ташкенбаева, З.А. Насырова Оценка состояния коронарного русла у больных острым инфарктом миокарда различной локализации и фибрилляцией предсердия A.O. Lakhanov, E.N. Tashkenbaeva, Z.A. Nasyrova Assessment of coronary artery status in patients with acute myocardial infarction of various locations and atrial fibrillation A.O. Laxanov, E.N. Tashkenbayeva, Z.A. Nasirova Turli joylashuvdagi o‘tkir miokard infarkti va bo‘lmachalar fibrillyatsiyasi bilan kasallangan bemorlarda koronar qon tomir tizimi holatini baholash.....	38
8	А.Р. Нарзуллаева, С.Дж. Касымова Анализ факторов риска развития и структурные особенности миокарда при острых формах ишемической болезни сердца A.R. Narzullaeva, S. J. Kasymova Analysis of risk factors for the development and structural features of the myocardial diabetes in acute forms of ischemic heart disease A.R. Narzullaeva, S. J. Kasymova Koroner yurak kasalligining o‘tkir shakllarida miyokardning rivojlanishi va strukturaviy xususiyatlari uchun xavf omillarini tahlil qilish.....	44

9	С.Т. Рахмонов, Х.И. Ибрагимов Влияние внутривенного введения препаратов железа на клинические исходы у пациентов с сердечной недостаточностью и дефицитом железа S.T. Rakhmonov, K.I. Ibragimov Effects of Intravenous Iron Supplementation on Clinical Outcomes in Patients with Heart Failure and Iron Deficiency S.T. Raxmonov, X.I. Ibragimov Yurak yetishmovchiligi va temir tanqisligi bo'lgan bemorlarda intravenoz temir preparatlarini klinik natijalarga ta'siri.....	49
10	Д.Р.Тайров Изучение характеристик метаболического синдрома и факторов риска поражения сердца при подагре по возрасту D.R. Tairov Study of the characteristics of metabolic syndrome and cardiac damage risk factors in gout disease by age D.R. Tairov Podagra kasalligida metabolik sindrom va kardial zararlanish xavf omillari xususiyatlarini yoshga bog'liq holda o'rganish.....	54
11	Э.Н.Ташкенбаева, С.К.Туйчиева, З.А.Насырова Клинические особенности метаболических нарушений у женщин с сердечно-сосудистой патологией E.N. Tashkenbaeva, S.K. Tuychieva, Z.A. Nasyrova Clinical features of metabolic disorders in women with cardiovascular pathology E.N.Tashkenbayeva, S.K.Tuychiyeva, Z.A.Nasirova Yurak-qon tomir kasalligi bo'lgan ayollarda modda almashinuvi buzilishlarining klinik xususiyatlari.....	59
12	Э.Н.Ташкенбаева, П.Х. Пулатова Цистатин С - ранний биомаркер почечной дисфункции у пациентов с сердечно-сосудистыми заболеваниями E.N. Tashkenbayeva, P.Kh. Pulatova Cystatin C - an early biomarker of renal dysfunction in patients with cardiovascular disease E.N. Tashkenbayeva, P.X. Pulatova Sistatin C - yurak qon-tomir kasalligi bilan og'riqan bemorlarda buyrak disfunktsiyasining erta biomarkeri.....	65
13	Ю.А. Филимонкина, В.В. Рафальский, Л.В. Михайлова Исследование влияния модифицируемых факторов сердечно-сосудистого риска на эффективность двойной антиагрегантной терапии у пациентов после инфаркта миокарда в Калининградской области Yu. A. Filimonkina, V. V. Rafalskiy, L.V. Mikhaylova Study of the influence of modifiable cardiovascular risk factors on the efficacy of dual antiplatelet therapy in patients after myocardial infarction in the Kaliningrad region Yu.A. Filimonkina, V.V. Rafalskiy, L.V. Mixaylova Kaliningrad viloyatida miokard infarktidan keyin bemorlarda ikki tomonlama antitrombotsitar terapiyaning samaradorligiga o'zgartirilishi mumkin bo'lgan yurak-qon tomir xavf omillarining ta'sirini o'rganish.....	72

АКТУАЛЬНЫЕ ВОПРОСЫ ФТИЗИАТРИИ И ПУЛЬМОНОЛОГИИ

14	Д.Н. Аджаблаева, Н.Н. Парпиева Современные эпидемиологические факторы риска реализации латентного туберкулеза в локальные формы у детей D.N. Adjablaeva, N.N. Parpieva Modern epidemiological risk factors for the realization of latent tuberculosis into local forms in children D.N. Ajablayeva, N.N. Parpiyeva Bolalarda yashirin silning mahalliy shakllariga o'tishining zamonaviy epidemiologik xavf omillari.....	77
15	П.О.Закирьяева., Ж.А.Исмаилов., З.С.Камалов Патогенетическая роль нарушений в цитокиновой системе при неспецифической интерстициальной пневмонии P.O.Zakiryayeva., J.A. Ismailov., Z.S.Kamalov Pathogenetic role of disorders in the cytokine system in non-specific interstitial pneumonia P.O.Zakiryayeva., J.A. Ismailov., Z.S.Kamalov Nospesifik interstitsial pnevmoniyada sitokin tizimidagi buzilishlarning patogenetik roli.....	81
16	Исмаилов Ж.А., Тиладов А.Н., У.И.Исмаилова Особенности улучшения качества жизни пациентов, страдающих бронхиальной астмой	

J.A.Ismailov, A.N.Tilavov, U.I.Ismoilova

Distinctive aspects of improving the quality of life for patients with bronchial asthma

J.A.Ismoilov, A.N.Tilavov, U.I.Ismoilova

Bronxial astma bilan kasallangan bemorlarning hayot sifatini yaxshilashning o'ziga xos jihatlari

85

17 Ж.А.Исмаилов, О.И. Байтов

Оценка эффективности реабилитации в постхимиотерапевтическом периоде у пациентов с раком легкого

J.A. Ismailov, O.I.Bayitov Evaluating the effectiveness of rehabilitation in the post-chemotherapy period for patients with lung cancer

J.A. Ismailov, O.I.Bayitov

O'pka saratoni bilan og'rigan bemorlarda kimyoterapiyadan keyingi davrda reabilitatsiya samaradorligini baholash

90



Ташкенбаева Элеонора Негматовна

Заведующая кафедрой внутренних болезней и кардиологии №2, д.м.н, профессор
Самаркандский государственный медицинский университет
Самарканд, Узбекистан

Пулатова Паризода Хамзаевна

Базовой докторант Самаркандского
Государственного медицинского университета

ЦИСТАТИН С - РАННИЙ БИОМАРКЕР ПОЧЕЧНОЙ ДИСФУНКЦИИ У ПАЦИЕНТОВ С СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ

For citation: E.N. Tashkenbayeva, P.Kh. Pulatova CYSTATIN C - AN EARLY BIOMARKER OF RENAL DYSFUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE. Journal of cardiorespiratory research. 2025, vol 6, issue 2, pp.65-71

 <http://dx.doi.org/10.26739/2181-0974/2025/6/2/12>

АННОТАЦИЯ

Проблема дисфункции почек и ее влияние на исходы в различных группах кардиологических больных продолжает широко использоваться. Дисфункция почек связана с рядом традиционных факторов риска сердечно-сосудистых заболеваний. Использование новых биомаркеров, в частности цистатина С, для выявления повреждения почек может способствовать улучшению раннего прогнозирования риска развития почечной недостаточности (РФ). Цистатин С удовлетворяет многим характеристикам в качестве идеального биомаркера, который может помочь не только в выявлении ранних форм повреждения почек, но и в оценке риска РФ, потребности в заместительной почечной терапии и риска смерти у пациентов отделений интенсивной терапии в кардиологических клиниках. Поражение почек при многих заболеваниях, в том числе и тех, которые изначально не рассматриваются как почечные, обуславливает необходимость разработки единых подходов к ведению пациентов с выявленной хронической РФ, особенно к ранней профилактике и лечению ее осложнений, таких как анемия, фосфорно-кальциевые метаболические нарушения, которые существенно ухудшают прогноз других заболеваний.

Ключевые слова: почечная дисфункция, ишемическая болезнь сердца, цистатин С.

Tashkenbayeva Eleonora Negmatovna

Head of the Department of Internal Diseases and Cardiology No. 2, Doctor of Medical Sciences, Professor
Samarkand State Medical University Samarkand, Uzbekistan

Pulatova Parizoda Khamzaevna

Basic doctoral student of Samarkand
State Medical University

CYSTATIN C - AN EARLY BIOMARKER OF RENAL DYSFUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE

ANNOTATION

The problem of kidney dysfunction and its impact on outcomes in different groups of cardiac patients continue to being widely used. Kidney dysfunction is associated with a number of traditional cardiovascular risk factors. The use of new biomarkers, cystatin C in particular, to identify kidney injury can contribute to the improvement of early prediction of a risk for renal failure (RF). Cystatin C satisfies many characteristics as an ideal biomarker that can assist in not only detecting the early forms of kidney injury, but also in assessing the risk of RF, the needs for renal replacement therapy, and the risk of death in intensive care unit patients in cardiac clinics. Kidney involvement in many diseases, including those that are not initially regarded as renal, necessitates the elaboration of uniform approaches to managing patients with identified chronic RF, especially to the early prevention and treatment of its complications, such as anemia, phosphorus-calcium metabolic disorders, which substantially worsen the prognosis of other diseases.

Key words: renal dysfunction, coronary heart disease, cystatin C.

Tashkenbayeva Eleonora Negmatovna

2-son ichki kasalliklar va kardiologiya kafedrası mudiri, t.f.d., professor

Samarqand davlat tibbiyot universiteti

Samarqand, O'zbekiston

Pulatova Parizoda Hamza qizi

Samarqand Davlat tibbiyot universiteti

Tayanch doktoranti

SISTATIN C - YURAK QON-TOMIR KASALLIGI BILAN OG'RIGAN BEMORLARDA BUYRAK DISFUNKSIYASINING ERTA BIOMARKERI

ANNOTATSIYA

Buyrak disfunktsiyasi muammosi va uning yurak qon-tomir kasalligi bilan og'rigan bemorlarning turli guruhlariga ta'siri keng qo'llanilmoqda. Buyrak disfunktsiyasi bir qator yurak-qon tomir xavf omillari bilan bog'liq. Buyrak shikastlanishini aniqlash uchun yangi biomarkerlardan, xususan, sistatin C dan foydalanish buyrak yetishmovchiligi xavfini erta bashorat qilishga yordam beradi. Sistatin C nafaqat buyrak shikastlanishining dastlabki shakllarini aniqlashda, balki buyrak o'rnini bosuvchi terapiya ehtiyojlarini va shifoxonalarda reanimatsiya bo'limidagi bemorlarda o'lim xavfini baholashda yordam beradigan ideal biomarker sifatida ko'plab xususiyatlarni ochib beradi.

Kalit so'zlar: buyrak disfunktsiyasi, yurak-qon tomir kasalligi, sistatin S.

Topicality. Since the mid-20th century, cardiovascular diseases (CVD) have been the leading cause of death and disability in the industrialized world, leading to a steady increase in healthcare costs. At the same time, experts from the World Health Organization predict a further increase in cardiovascular morbidity and mortality in both economically developed and developing countries due to population aging and lifestyle factors [1]. Epidemiologists pay special attention to the early detection and correction of risk factors (RF) that determine the destabilization of the course of diseases associated with atherosclerosis, including coronary heart disease (CHD). Numerous studies have proven the role of renal dysfunction (RD) as an independent predictor of cardiovascular morbidity and mortality. It has been shown that a moderate decrease in renal function increases the risk of developing arterial hypertension (AH), CHD, heart failure (HF) and death from CVD [1, 2]. Chronic kidney disease (CKD) is defined as kidney damage or decreased kidney function for 3 months or more, i.e. the presence of chronic DP. The disease is classified into 5 stages, which differ in patient management tactics, the risk of developing end-stage renal failure (ESRF) and cardiovascular complications (CVC). Anamnestic indication of the presence of morphological kidney pathology is not necessary for verification of CKD. It has been established that a patient with CKD is 20 times more likely to die from heart disease than from end-stage kidney disease [3]. At the same time, in patients with end-stage CKD, CVD is the cause of 43-50% of all deaths [4], which determines the relevance of identifying DP in patients with CVD and the need for their aggressive prevention in patients with CKD. The problem of DP and its impact on outcomes in various groups of cardiac patients continues to be widely discussed. The increase in the number of patients with coronary heart disease with DP can be explained by both an increase in the proportion of elderly patients (given the known association of decreased renal function with age [5]) and the influence of increasingly common background and concomitant pathology (type 2 diabetes mellitus - DM-2, hypertension, chronic heart failure - CHF). It is known that mortality due to acute DP in the general population is 41%; among patients with myocardial infarction (MI) with ST segment elevation - 55%, among patients with MI without ST segment elevation - 22% [6]. According to F. Masoudi et al. [7], in the USA, among hospital patients, normal

renal function was determined in only 16%, mild decrease in renal function (glomerular filtration rate - SFR 60-89 ml/min/1.73 m²) - in 43%, moderate (SFR 30-59 ml/min/1.73 m²) - in 32% and severe (SFR 30 ml/min/1.73 m²) - in 9%. Mortality in hospitals in patients with concomitant CKD is 21% compared to 6-8% in the general population of patients with MI [8]. The presence of DP is associated with a number of traditional risk factors for the development of CVD. In our previously published studies, we have shown that the prevalence of DP among patients with ST-segment elevation MI is 37%, it is more often detected in older patients, women, as well as in patients with a complicated cardiovascular history and more severe manifestations of acute HF according to Killip. In addition, patients with DP are less likely to undergo percutaneous interventions, which is an additional factor worsening their prognosis.

The purpose of the study. Decreased renal function is associated with such background (for coronary heart disease) diseases as hypertension, diabetes mellitus (DM), CHF and increases the likelihood of death during the hospital period [9]. Thus, among patients with CHF, kidney pathology occurs in 44% [10]. The problem of acute kidney injury (AKI) is also relevant when performing therapeutic and diagnostic radiological procedures with contrast. The prevalence of nephropathy induced by a contrast agent (contrast-induced - CIN) in the general population does not exceed 2% [11]. In high-risk groups (elderly patients, those with previous kidney disease, diabetes, heart failure, arterial hypotension, anemia, dehydration, and those using nonsteroidal anti-inflammatory drugs), the prevalence of CIN reaches 20-30% [11]. There is evidence that taking rosuvastatin at a dose of 10 mg/day 2 days before angiographic examination and for 3 days after it significantly reduces the risk of developing contrast-induced AKI [12].

It is also important to remember about assessing renal function when prescribing any long-term drug therapy, which is especially important for drugs in the groups of anticoagulants, hypoglycemic drugs (HDA) and statins. The problem of undiagnosed CKD is especially relevant among patients with diabetes. According to registry studies, almost 40% of patients with type 2 diabetes are characterized by the presence of CKD of various stages, which, however, is not taken into account when prescribing oral HDA. This fact is the cause of therapy-

induced transient episodes of hypoglycemia, which naturally worsens the prognosis of the underlying disease [13]. At the same time, most antidiabetic drugs have limitations, and in some cases, contraindications when prescribed to patients with DP. The daily dose of HDA should be adjusted depending on the SCF, this is especially true for metformin, since it is contraindicated in moderate and severe DP [14]. New antidiabetic drugs are better tolerated by patients with severe renal impairment, although clinical experience remains limited for many of them [15]. For patients with a cardiological profile, the problem of dosing and indirect anticoagulants is relevant. In a multicenter prospective study EPICA, which included 4093 patients over 80 years old who took vitamin K antagonists for atrial fibrillation (AF), the prevalence of CKD, determined by SCF, was assessed. The risk of bleeding was determined using the Cockcroft-Gault and MDRD (Modification of Diet in Renal Disease) formulas. It was found that the risk of bleeding is higher in patients taking vitamin K antagonists with moderate and severe atrial fibrillation, regardless of the formula for determining SCF. These data confirm the need for more frequent monitoring of blood coagulation parameters in elderly patients [16]. The ROCKET-AF study assessed the efficacy and safety of rivaroxaban, a new factor X inhibitor.

Materials and methods of research. The study included 14,264 patients with non-valvular AF and additional stroke risk factors compared with standard warfarin therapy under the control of an international normalized ratio of 2 to 3 [17]. Rivaroxaban is known to be primarily metabolized by the liver, but about 1/3 of it is metabolized by the kidneys [18]. Patients with an SCF of 30 ml/min were excluded from the study, while the daily dose of rivaroxaban was reduced from 20 to 15 mg in patients with an SCF of 30 to 49 ml/min. It has been established that new anticoagulants (X-factor inhibitors), such as rivaroxaban, dabigatran and apixaban, are not associated with a higher risk of bleeding in patients with non-valvular AF and concomitant CKD [19]. Thus, DP is associated with a number of traditional risk factors for the development of CVC, while it has not only an indirect but also an independent effect on the occurrence of adverse outcomes in patients with coronary heart disease; its identification is an important condition for safe treatment. Currently, the diagnosis of AKI or chronic kidney injury is based on the detection of changes in the volume of hourly diuresis, the concentration of creatinine in the blood and SCF. It is known that an increase in the level of creatinine in the blood serum can depend not only on kidney function, but also on many other factors not associated with the excretory system [20], in particular, on the pathology of the musculoskeletal system and liver. The main limitation of kidney injury diagnostics using creatinine level assessment is its late increase: it has been determined that in many cases it occurs only 24-48 hours after kidney injury.

Results of the study. The explanation may be that the kidneys have a significant functional reserve, so the creatinine concentration does not change until 60% of the renal parenchyma is morphologically lost. Renal function itself is traditionally assessed using the formulas for calculating the SCF: Cockcroft-Gault and MDRD. The MDRD formula was developed on the basis of a study involving 1,628 people, of whom 1,070 were randomly selected and 500 people formed the control group. The aim of this study was to determine the most accurate formula for calculating the SCF. Calculations were made using stepwise regression analysis. The results of the study showed that the MDRD formula calculates the SCF more

accurately and, accordingly, has a higher sensitivity compared to the calculation of creatinine clearance in determining the stage of DP [21]. The advantages of the MDRD formula are that it is derived from the determination of the renal clearance of 125I-iothalamate in a large group of patients, both Caucasian and Negroid, with a wide range of kidney diseases. The formula allows one to estimate the SCF standardized by body surface area. There are two versions of the MDRD formula: full and abbreviated. To calculate the SCF using the full (original) formula, a number of biochemical parameters are required along with serum creatinine. To use the abbreviated MDRD formula, only demographic data (gender, age, race) and serum creatinine level are required. The formula is designed for men, and a correction factor is proposed for women. In the MDRD study, which evaluated the Cockcroft-Gault formula in one laboratory, it overestimated the SCF by 23%. In addition, the Cockcroft-Gault formula overestimates the CrCr at a SCF level of 60 ml/min. Thus, the assessment of DP, especially at normal or borderline creatinine levels, is more accurately carried out using the MDRD formula and, in general, the presented formulas reflect different processes. However, MDRD is not ideal either, since errors may be detected in patients with initial manifestations of DP. It is clear that for prospective and early diagnostics of AKI at the earliest possible stage according to the RIFLE criteria [23] adopted in leading clinics, more sensitive markers than an increase in the level of creatinine in the blood are needed.

Discussion. The limitations of the use of SCF are reduced to the listed reasons, since the main criterion for calculating the SCF is the same level of creatinine in the blood. Thus, in recent years, there has been great interest in the search for new, highly sensitive biological markers that allow one to determine renal dysfunction at the initial stages and to assess the individual risk and prognosis of DP development in a patient, as well as to monitor the effectiveness of treatment of the underlying disease in relation to potential nephrotoxicity. It is assumed that the "ideal" biomarker should be produced by damaged kidney cells, its level should increase immediately after even a small volume of damage to the renal tissue, when it is still potentially reversible for the organ. In addition, the level of such a biomarker should be proportional to the degree of damage for potential riskometry and monitoring of treatment effectiveness. It should decrease soon after improvement of kidney function. Such a marker should be collected for laboratory testing in a non-invasive way, provide the possibility of simple and rapid measurement, reflect the pathophysiology of the disease and have high prognostic significance [24].

Findings. According to many authors, the most promising biomarkers for early diagnostics of kidney damage are those not associated with impaired renal filtration function, but reflecting morphological damage to the renal parenchyma, proliferation, differentiation and apoptosis of cells, immune response disorders and production of cytokines and chemokines [25]. Based on the results of experimental studies, a number of biomarkers have been proposed for early diagnostics of DP, including interleukin-18 (IL-18), kidney injury molecule type 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and cystatin C [26]. IL-18 is a pleiotropic proinflammatory cytokine that plays an important role in the inflammatory cascade [27]. Thus, the results of a number of studies have shown a slight increase in its content in kidney tissue under conditions of experimentally induced damage and its key role in the induction of ischemic kidney damage [28, 29]. In isolated damage to the proximal

tubules of the nephron in mice, an increase in the content of IL-18 in the hypoxic zone and an increase in its level in the urine in the ischemic variant of AKI were detected [30]. This prompted a number of clinical studies aimed at proving the possible role of IL-18 as a biomarker of AKI. There is evidence that the expression of IL-8 may be associated with the progression and damage of the atherosclerotic plaque [31]. In the study by C. Parickh et al. [32], it was demonstrated that elevated concentrations of IL-18 are an independent risk factor for the development of CVD. Another biological marker that can potentially be considered as an early indicator of AKI is KIM-1, which is determined in urine. This is a transmembrane protein with immunoglobulin and mucin domains, first described in 1998 [33]. In intact renal tissue, it is contained in small amounts, but after renal ischemia, its level in regenerating proximal tubules increases significantly. As shown in experimental models, an increase in the KIM-1 level is associated with ischemic kidney injury and is not always accompanied by an increase in blood urea nitrogen and creatinine [34]. Numerous studies show that KIM-1 is a highly sensitive and specific marker of kidney injury and has a high prognostic value in predicting the risk of developing acute renal failure [35] in patients with CVD. NGAL is a protein with a molecular weight of 25 kDa, initially detected in neutrophils and somewhat later in small amounts in the epithelium of renal tubules. In healthy humans, NGAL is not detected in the blood or is present in small concentrations in various tissues or organs with activated epithelial cells [36]. In ischemic kidney injury, its expression in tubular epithelial cells increases many times, its concentration in the blood and excretion in the urine increase, outpacing the increase in creatinine concentration by 24-48 hours [37].

In a study devoted to the prognostic role of NGAL in urine in patients after open heart and vascular surgery under conditions of prolonged artificial circulation, it was found that the NGAL level in urine increased 2-6 times already 2 hours after surgery, while creatinine and urea concentrations remained within the permissible values. 24 hours after surgery, the NGAL level in urine returned to baseline. An increase in the concentration of creatinine in the blood and urea was noted only on the 2nd day [38]. Thus, lipocalin has proven its effectiveness in early prediction of the risk of AKI, especially in patients with coronary artery disease, after planned coronary artery bypass grafting (CABG) [39]. Another actively discussed biological marker of early kidney injury, cystatin C, is a non-glycosylated protein with a molecular weight of 13.4 kDa and an isoelectric point at pH 9.3. Belongs to the family of cysteine proteinase inhibitors, is identical to post- γ -globulin and has two disulfide bonds located in the C-terminal region of the molecule. This protein is encoded by the CS73 gene, localized on the short arm of chromosome 20 [40]. As early as 1979, it was suggested that serum cystatin C could serve as a marker reflecting SCF [40]. In patients on hemodialysis, its level was 13 times higher than that in healthy individuals [40]. Early studies (1984-1985) showed that serum cystatin C was indeed a marker of SCF and was not inferior to creatinine in early studies [41]. In addition, it has been shown that the serum cystatin C level is a more reliable marker of SCF than other low-molecular proteins (β 2-microglobulin, retinol-binding protein, and complement factor D) [41]. Currently, these facts are explained by the fact that cystatin C is characterized by a constant rate of production by almost all nucleated cells of the body, free glomerular filtration, is completely metabolized in the kidneys and is not subject to tubular secretion, which makes it an almost ideal marker for

determining SCF [24]. It is generally accepted that the serum cystatin C level does not depend on race, gender, muscle mass, and its concentration in plasma is relatively stable [42]. According to some data, with increasing age, the cystatin C level slightly increases, which is associated with a natural decline in kidney function with aging [42]. However, there is currently evidence that the formation of cystatin C is not constant. The main factors influencing the serum cystatin C level are considered to be height and body weight, smoking, alcohol consumption, C-reactive protein (CRP) level, as well as systemic inflammatory diseases such as rheumatoid arthritis and steroid therapy [43]. Some studies have noted a relationship between increased serum cystatin C levels and obesity [44], which raised the question of the mechanisms of cystatin C hyperproduction by adipocytes and the limitation of the use of cystatin C for assessing GFR in patients with an increased body mass index (BMI) [44]. Another extrarenal factor influencing the cystatin C level is thyroid function: in hyperthyroidism, its level increases, while in hypothyroidism, it decreases [45]. The advantage of cystatin C over serum creatinine has been proven in patients with diabetic nephropathy, when the GFR remains normal or increased. It has been established that there is a pronounced disproportion between the SCF calculated using the MDRD formula based on the concentration of creatinine in the blood serum and cystatin C: cystatin C turned out to be a more accurate marker of the progression of renal dysfunction than creatinine, with a SCF $> 60 \text{ ml} / \text{min} / 1.73 \text{ m}^2$, which can be used for early prediction of renal dysfunction in diabetes mellitus [46]. It has also been shown that cystatin C is superior to creatinine in terms of prognostic significance in relation to assessing the SCF and predicting the risk of death and developing CVD [47]. Numerous studies demonstrate a strong relationship between the level of cystatin C and the risk of developing CVD. Elevated cystatin C levels are associated with both progression of renal impairment and increased risk of all-cause mortality and development of CV events such as MI, ischemic stroke, HF, as well as peripheral arterial disease, severity of atherosclerotic process, and metabolic syndrome [47]. Some authors suggest that elevated cystatin C levels may be associated with high CV mortality regardless of renal impairment [48]. Elevated cystatin C levels in patients with MI are associated with increased mortality. In addition, it was found that in patients with multiple atherosclerotic lesions of the coronary arteries according to coronary angiography, the concentration of cystatin C is higher than in patients with lesions of only one coronary artery [49]. According to data published in the Annals of Internal Medicine, cystatin C predicts the risk of developing HF more accurately than serum creatinine, a more commonly used parameter of renal function. Elevated cystatin C levels were associated with an increased risk of developing HF even after adjustment for confounders, while creatinine concentration was not significantly associated with the risk of developing HF [22]. In a recent study evaluating the prognostic role of cystatin C in relation to the development of hospital complications in patients undergoing CABG, no statistically significant differences were found in serum creatinine concentrations and SCF either before or after surgery between patients in the low, intermediate, and high risk groups according to the EuroSCORE scale. At the same time, with an increase in risk according to the EuroSCORE scale, the concentration of cystatin C in the blood serum increases. There were no significant differences in serum creatinine concentrations and SCF in patients with favorable and unfavorable outcomes either before or after CABG. At the same

time, the concentration of cystatin C in patients with an unfavorable outcome was significantly higher than in patients with a favorable outcome one day before CABG and on the 7th day after it [24]. In a study by Russian authors, a prognostic model for the risk of complicated postpericardiotomy syndrome was developed in patients who underwent heart valve replacement. A high risk of developing postpericardiotomy syndrome is established based on a serum cystatin C level of more than 5.45 mg/l [47]. In a study by A.P. Rebrov et al. [48], a relationship was determined between the level of cystatin C and target organ damage in hypertension, including hypertensive nephropathy. The study group included 94 patients (men and women) diagnosed with hypertension aged 30-65 years. It was found that the median serum cystatin C level in individuals with hypertension was 1029.4 ng/ml (772; 1216), minimum — 350 ng/ml, maximum — 2371.95 ng/ml. Relationships were found between the cystatin C level and age over 50 years, obesity, stage and risk of hypertension, heart failure. In men under 50 years, a more rapid and statistically significant increase in the cystatin C level was determined than in women. In addition, in women, an increase in serum cystatin C was detected with hypertension duration of more than 10 years. Relationships have been established between the level of cystatin C and SCF, left ventricular myocardial mass index, the presence of atherosclerotic plaques in the carotid arteries and an increase in the thickness of the intima-media complex, and the size of the heart cavities [48]. According to S. Zhao et al. [49], cystatin C is a marker that reflects not only AKI, but also oxidative status. In addition, it was found that the combination of elevated concentrations of cystatin C, total bilirubin and CRP in patients undergoing percutaneous coronary intervention are independent risk factors for in-stent restenosis. Recent studies have shown that DP is associated with microbleeds in the brain. It has been

proven that elevated serum cystatin C concentrations are associated with the presence of microbleeds in the brain in patients with acute stroke, regardless of other risk factors, such as gender, age and risk factors for the development of CVE [50]. In addition, older age, BMI, and CRP levels are independently associated with cystatin C levels. All of the above determines serious limitations of the most common methods for determining renal failure using the traditional indicator of kidney damage — creatinine. Currently, many biomarkers are known that reflect kidney damage at the earliest stages, many of which have sensitivity and specificity, as well as reproducibility, that are quite acceptable for clinical use. In addition, the special value of a number of markers is determined by their versatility — the possibility of using them not only for diagnosing renal failure, but also for predicting cardiovascular events. Perhaps the most promising in this regard is cystatin C, since its elevated concentrations can be associated with the risk of developing not only nephropathy, but also fatal cardiovascular events. The use of “new” biomarkers, in particular cystatin C, to detect kidney damage can help improve early prediction of the risk of developing renal failure. In our opinion, cystatin C meets many characteristics of an “ideal” biomarker, which can be used not only to detect early forms of kidney damage, but also to assess the risk of developing renal failure, the need for renal replacement therapy, and the risk of death in patients in intensive care units of cardiology clinics. Kidney involvement in many diseases, including those not initially considered renal, makes it necessary to develop unified approaches to the management of patients with identified chronic renal failure, especially in terms of early prevention and treatment of its complications: anemia, phosphorus-calcium metabolism disorders, which significantly worsen the prognosis of other diseases.

Литература/References/Iqtiboslar:

1. Агарков, Н.М. Общественное здоровье и здравоохранение / Н.М. Агарков, О.Л. Фабрикантов, С.И. Николашин [и др.]. - М.: ООО «Издательство КноРус», 2021. - 624с.
2. Авдошина, С.В. Оценка риска развития острого повреждения почек у больных с острой сердечно-сосудистой патологией без инвазивного вмешательства / С.В. Авдошина, М.А. Ефремовцева, С.В. Виллевалде и соавт. // Кардиология. - 2019. - Т. 59 - № 12Б - С. 46-56.
3. Бекметова Ф.М., Арзиева Ю.М. Эхокардиографические изменения сердечной функции у людей пожилого возраста при ишемической болезни сердца // Oйental Renaissance: Innovative, educational, natural and social sciences. — 2023. - Vol. 3(9). — С. 761 -769.
4. Бойцов, С.А. Возможности диспансерного наблюдения в снижении смертности от ишемической болезни сердца / С.А. Бойцов, С.И. Проваторов // Терапевтический архив. - 2023. - Т. 95, № 1. - С. 5-10.
5. Бойцов, С.А. Современное содержание и совершенствование стратегии высокого сердечно-сосудистого риска в снижении смертности от сердечнососудистых заболеваний / С.А. Бойцов, О.М. Драпкина // Терапевтический архив.- 2021. - Т. 93, № 1. - С. 4-6.
6. Влияние почечной дисфункции на сердечнососудистую систему. Возможности ранней диагностики почечной дисфункции / Б. Ж. Иманов, И. Т. Муркамилов, И. С. Сабилов, А. Ш. Сарыбаев // Архивъ внутренней медицины. - 2018. - Т. 8, № 4 (42). - С. 260-265.
7. Возможность контроля липидного профиля у пациентов, перенесших стентирование коронарных артерий, с помощью дистанционного мониторинга по результатам наблюдения в течение 6 месяцев / А.К. Осокина, А.В. Потехина, А.Ю. Филатова [и др.] // Вестник Всероссийского общества специалистов по медикосоциальной экспертизе, реабилитации и реабилитационной индустрии. -2020. - № 3. - С.56-64.
8. Голощапов-Аксенов, Р.С. Исследование приверженности пациентов с сердечно-сосудистыми заболеваниями старших возрастных групп хирургическому лечению и оценка клинической эффективности рентгенэндоваскулярного лечения / Р.С. Голощапов-Аксенов, О.В. Рукодайный, П.С. Волков // Казанский медицинский журнал. - 2022. - Т. 103, № 1. - С. 35-43.
9. Григорьев В.С., Петросян К.В., Абросимов А.В. Анатомическая ткаля оценки риска SYNTAX Score — инструмент определения тяжести поражения коронарного русла и прогнозирования исходов эндоваскулярных

вметательств /Жреативная кардиология. — 2019. - № 13 (2). — С. 159—172.

10. Гулябин, К.Р. Ишемическая болезнь сердца / К.Р. Гулябин // Справочник врача общей практики. - 2022. - № 1. - С. 63-66.

11. Давыдов, В.В. Причины развития и прогрессирования кардиоренального синдрома при хронической сердечной недостаточности. Методы профилактики / В. В. Давыдов, Е. Л. Арехина // Российский кардиологический журнал. - 2021. - Т. 26 - № 1 - С. 180-185.

12. Динамика заболеваемости взрослого населения острыми формами ишемической болезни сердца и смертности от них в Российской Федерации в 2012—2017 гг. / Е.В. Огрызко, М.А. Иванова, А.В. Одинец [и др.] // Профилактическая медицина. - 2019. - Т. 22, № 5. - С. 23-26.

13. Донченко, Е.В. Ишемическая болезнь сердца. Что это и как предотвратить / Е.В. Донченко // Студенческий вестник. - 2018. - № 30-2(50). - С. 25-28.

14. Евразийские клинические рекомендации по диагностике и лечению стабильной ишемической болезни сердца (2020-2021) / Ю.А. Карпов, О.Л. Барбараш, А.А. Бощенко [и др.] // Евразийский кардиологический журнал. - 2021. № 3. - С. 54-93.

15. Жигалова, М. С. Выбор оптимальной схемы лечения больных с синдромом ишемии-реперфузии, осложненным острым повреждением почек / М. С. Жигалова, Д. Е. Кутепов, И. Н. Пасечник // Кремлевская медицина. Клинический вестник. - 2020. - № 1. - С. 58-63.

16. Жмуров, Д.В. Ишемическая болезнь сердца / Д.В. Жмуров, М.А. Парфентева, Ю.В. Семенова // Colloquium-journal. - 2020. - № 29-1(81). - С. 32-37.

17. Значение скрининга хронической болезни почек у пациентов с сердечно-сосудистыми заболеваниями / Класова А.Т., Агранович Н.В., Кнышова С.А., Алботова Л.В., Александрова О.А. //Вестник молодого ученого. - 2019. - Т. 8. - № 3. - С. 106-109.

18. Зуева, Т. В. Коморбидность почечной и кардиальной патологии / Т. В. Зуева, Т. В. Жданова, С. Е. Уразлина // Медицинский вестник Северного Кавказа. - 2019. - Т. 14, № 4. - С.711-717.

19. Зыков М.В., Кашталап В.В., Быкова И.С., Герман А.И., Каретникова В.Н., Барбараш О.Л. Связь мультиморбидности с риском развития сердечно-сосудистых осложнений у пациентов с острым коронарным синдромом // Кардиологический вестник. 2018. Т. 13. № 2. С. 59-65.

20. Керчева, М.А. Роль макрофагов в формировании кардиоренального синдрома при инфаркте миокарда / М.А. Керчева, В.В. Рябов // Российский кардиологический журнал. - 2021. - Т. 26 - № 4 - С. 143-148.

21. Кремнева, Л.В. Кардиоренальный синдром в ранние сроки коронарного шунтирования / Л.В. Кремнева, О.В. Абатурова, А.Ю. Ефанов и соавт. // Терапевтический архив. - 2018. - Т. 90 - № 6 - С. 35-40.

22. Кухарчук, В.В. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020). / В.В. Кухарчук, М.В. Ежов, И.В. Сергиенко и соавт. // Евразийский кардиологический журнал. -2020. - № 2 - С. 6-29.

23. Миронова, О.Ю. Анемия как фактор риска развития контраст-ассоциированного острого повреждения почек / О.Ю. Миронова, А.Д. Деев, П.Г. Лакотка и соавт. // Терапевтический архив. - 2020. - Т. 92 - № 12 - С. 4852.

24. Евразийские клинические рекомендации по диагностике и лечению острого коронарного синдрома с подъемом сегмента ST (ОКСпST) / И.И. Староверов, Р.М. Шахнович, М.Ю. Гиляров [и др.] // Евразийский кардиологический журнал. - 2020. - № 1. - С. 4-77.

25. Ишемическая болезнь сердца у лиц молодого возраста: распространенность и сердечно-сосудистые факторы риска / Е.Ю. Андреев, И.С. Явелов, М.М. Лукьянов [и др.] // Кардиология. - 2018. - Т. 58, № 10. - С. 53-58.

26. Ишемическая болезнь сердца: вопросы патогенеза, диагностики, лечения и экспертизы нетрудоспособности / Д.Ю. Гамаюнов, В.А. Хаптанова, Н.М. Балабина [и др.] // Медицина и высокие технологии. - 2021. - №2 3. - С. 41-48. - DOI 10.34219/2306-3645-2021-11-3-41-48.

27. Канорский, С.Г. Ишемическая болезнь сердца с высоким риском осложнений: как идентифицировать таких пациентов и выбирать тактику ведения? / С.Г. Канорский // Рациональная фармакотерапия в кардиологии. - 2020. - Т. 16, № 3. - С. 465-473.

28. Карпов, Ю. А. О снижении риска осложнений при плановом стентировании коронарных артерий / Ю. А. Карпов // Актуальные вопросы кардиологии. - 2022. - № 2. - С. 3-11.

29. Карпов Ю. А. Европейские рекомендации по ведению пациентов с хроническими коронарными синдромами 2019 г. : в фокусе новое направление профилактики событий / Ю.А. Карпов // Атмосфера. Новости кардиологии. - 2019. - № 2. - С. 3-12.

30. Кисляк, О. А. Вазопротекторное действие статинов и современный взгляд на место статинов в первичной и вторичной профилактике сердечно-сосудистых заболеваний / О. А. Кисляк, О. В. Сергиенко, М. Н. Давиденко. — 2019. — С. 49-56.

31. Кобзева Н.Д., Терентьев В.П., Батюшин М.М. Прогнозирование риска формирования постконтрастного острого повреждения почек у больных острым коронарным синдромом // Терапия. - 2020, №4. - С.124-130.

32. Кулакова, Е. Н. Определение и критерии острой болезни почек: систематическое обзорное исследование литературы / Е. Н. Кулакова, Т. Л. Настаушева, И. В. Кондратьева // Нефрология и диализ. - 2020. - № 1. - С. 71-83.

33. Медико-социальная экспертиза при ишемической болезни сердца / Н.М. Золотарева, И.Е. Михайловская, К.А. Моница, М.А. Золотарева // Научно-медицинский вестник Центрального Черноземья. - 2019. - №75. - С. 92-95.

34. Почечная дисфункция у пациентов с артериальной гипертензией и

метаболическим синдромом и роль цистатина С в ее ранней диагностике/ Алботова Л.В, Агранович Н.В., Л.А. Пилипович, Лихачева А.П., Классова А.Т./ Вестник молодого ученого. – 2020. - №2. – С. 41 – 46.

35. Протасов, К.В. Расчетная скорость клубочковой фильтрации на основе цистатина С после чрескожного коронарного вмешательства в прогнозе госпитальной летальности при остром инфаркте миокарда / К.В. Протасов, О.С. Донилова, Е.В. Батунова // Российский кардиологический журнал. - 2021.- Т. 26 - № 12 - С. 4642.

36. Роль цистатина С в ранней диагностике процессов почечной дисфункции у пожилых пациентов с артериальной гипертензией и метаболическими нарушениями /Агранович Н.В., Алботова Л.В., Лихачева А.П./ Современная наука: Актуальные вопросы теории и практики. Серия: «Естественные и технические науки». – 2020. - №9. – С. 133-138.

37. Роль цистатина С в прогнозировании риска развития неблагоприятных исходов коронарного шунтирования в госпитальном периоде / К. С. Шафранская, В. В. Кашталап, А. А. Кузьмина [и др.] // Российский кардиологический журнал. - 2013. - № 3. - С. 45-50. DOI: 10.15829/1560-40712013-3-45-50